Given these considerations, antipsychotic drugs should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that 1) is known to respond to antipsychotic drugs, and 2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.
The intravenous route is not FDA approved and is generally not recommended except when no other alternatives are available. Intravenous administration appears to be associated with a higher risk of QT prolongation and torsade de pointes (TdP) than other forms of administration. The manufacturer recommends ECG monitoring for QT prolongation and arrhythmias if IV administration is required. A dose in the range of 1 to 5 mg IV has been suggested, with the dose being repeated at 30 to 60 minute intervals, if needed. A maximum IV dose has not been established. The lowest effective dose should be used in conjunction with conversion to oral therapy as soon as possible.
If you are eligible, you may be able to lower your out-of-pocket costs for STELARA®, including deductible, co-pay, and coinsurance medication costs. With Janssen CarePath Savings Program for STELARA®, eligible patients pay just $5 per dose for their STELARA® medication costs, with a $20,000 maximum program benefit each calendar year. Patients using Medicare, Medicaid or any other federally-funded programs to pay for STELARA® are not eligible to participate in the program. Before the calendar year ends, you will receive information and eligibility requirements for continued participation in the program. There is no income requirement.